Indium Oxyquinoline

CHEMBL2110573 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

This compound is used in nuclear medicine to label white blood cells or other cells outside the body with radioactive indium-111, which are then reinjected to track inflammation, infection, or tumors inside the body. The oxyquinoline (oxine) acts as a carrier to move indium across cell membranes.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

This compound is used in nuclear medicine to label white blood cells or other cells outside the body with radioactive indium-111, which are then reinjected to track inflammation, infection, or tumors inside the body. The oxyquinoline (oxine) acts as a carrier to move indium across cell membranes.

Yes, Indium Oxyquinoline is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2110573. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.